ArticleActa dermato-venereologica2024
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
Article in Acta dermato-venereologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Efficacy and safety of the JAK1 inhibitor abrocitinib for moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis.American journal of clinical dermatology · 2026Pooled it
- Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Pooled it
- Clinical and inflammatory determinants of successful abrocitinib dose reduction in atopic dermatitis: a real-world cohort study with implications for treatment optimization.Annals of medicine · 2026Article
- Long-Term Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A Real-World, Retrospective Study.Dermatology and therapy · 2026Article
- Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD Registry.Dermatology and therapy · 2026Article
- Real-World Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A 16-Week Single-Center Retrospective Cohort Study Compared with Upadacitinib and Baricitinib.Dermatology and therapy · 2026Article
- Optimizing Abrocitinib Use for Atopic Dermatitis in India: Expert Recommendations for Patient Selection, Dosing, and Long‑Term Remission.Clinical, cosmetic and investigational dermatology · 2026Article
- Successful Treatment of Alopecia Areata With One JAK Inhibitor After Failure of Other JAK Inhibitors.JAMA dermatology · 2025Article
- Switching from Dupilumab to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Podcast Article.Dermatology and therapy · 2025Article
- Article
- The Dual-Edged Sword: Risks and Benefits of JAK Inhibitors in Infections.Pathogens (Basel, Switzerland) · 2025Review
- Comparative Analysis of the Efficacy of Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis.Clinical, cosmetic and investigational dermatology · 2025Article
- Risk factors that limit use of oral JAK inhibitors in chronic hand eczema: Findings from the Danish Skin Cohort.JAAD international · 2024Article
- Real-world Experience of Abrocitinib on Difficult-to-treat Hand Eczema in Chinese Patients.Acta dermato-venereologica · 2024Article
- Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review.Dermatology and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety of abrocitinib in patients with atopic dermatitis treated in daily practice. In a subgroup, the effectiveness of abrocitinib on hand eczema was evaluated. A total of 103 patients from the BioDay registry were included in the study: week 4 (n = 95), week 16 (n = 61) and week 28 (n = 39). At week 28, the Eczema Area and Severity Index (EASI)-50/75/90 was achieved by 81.8%, 57.6%, and 18.2%, respectively, and the weekly average pruritus numerical rating scale ≤ 4 by 62.9%. The effectiveness of abrocitinib was not significantly different between dupilumab non-responders and dupilumab-naïve patients/responders, and between upadacitinib non-responders and upadacitinib-naïve patients/responders. Mean ± standard deviation Hand Eczema Severity Index decreased from 27.4 ± 27.7 at baseline to 7.7 ± 12.1 at week 28 (n = 31). Thirty-two patients (31.1%) discontinued treatment due to ineffectiveness (n = 17), adverse events (n = 9) or both (n = 3). The most frequently reported adverse event was nausea (n = 28). In conclusion, abrocitinib is an effective treatment for atopic dermatitis and can be effective for patients with previous inadequate response to dupilumab or upadacitinib. Furthermore, hand eczema can improve in patients treated with abrocitinib for atopic dermatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.